- Adding hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) results in a substantial gain in quality-adjusted life years (QALYs) in patients with stage III ovarian cancer.
- The resulting incremental cost-effectiveness ratio (ICER) was within the current willingness-to-pay threshold in the Netherlands (€80,000/QALY).
Why this matters
- Findings support for reimbursing treatment costs in patients undergoing interval CRS with HIPEC in other countries with comparable health care systems.
- Cost-efficacy analysis of data from the OVHIPEC trial.
- 245 patients with stage III ovarian cancer were randomly assigned to receive interval CRS with or without HIPEC.
- Funding: None disclosed.
- Total health care costs were €70,046 in patients undergoing interval CRS vs €85,791 in those receiving interval CRS+HIPEC.
- The mean QALYs in the interval CRS group were 2.12 and 2.68 in the interval CRS+HIPEC group.
- The resulting ICER €28,299/QALY for HIPEC+CRS was within the willingness-to-pay threshold.
- The utility for recurrence-free survival, the number of hospitalization days, and the utility for recurrent disease with grade 3-4 toxicity affected the calculated ICER most.
- Costs of surgery, diagnostic tests, the administered regimens, and toxicities and recurrences were based on assumptions.